UCB’s ongoing work and unwavering focus keep people living with MG at the heart of everything we do, and we are committed to finding solutions for rare diseases, like MG, with a high degree of patient need by delivering purposeful innovations and differentiated solutions, creating value that cannot be expressed in numbers alone. 

This month in honor of Myasthenia Gravis (MG) Awareness Month, we have an opportunity to elevate the voices and needs of people with MG who remind us each day that our collective efforts can directly impact the everyday lives of MG patients – especially during times when immunocompromised individuals can face even more challenges than usual.

With more than 20 years of experience in caring for people living with epilepsy, our goal has always been to know and understand the day-to-day experiences of people living with the disease better than anyone. Over the past year this has been especially true, and the challenges we’ve faced have reinvigorated our commitment to the overall emotional and physical well-being of patients. Read more from UCB’s Head of U.S. Neurology, Mike Davis, about how UCB is finding new ways to better connect with patients and improve their day-to-day experience.

This Rare Disease Day, we’re continuing to raise awareness about seeing people in need and our commitment to innovating and finding solutions for patients living with rare diseases. 

Last week, UCB researchers from across the country gathered virtually for the PhRMA Researcher Fly-In where more than 70 industry researchers engaged with Members of Congress. Read their stories. 

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

This Rare Disease Week, we continue to raise awareness about the need for continued innovation and development for rare diseases. At UCB, we have a fundamental commitment to people living with severe diseases, their caregivers, and their families, to help them to live their best lives. This means innovating to bring differentiated solutions with unique outcomes, offering the best individual experience, and ensuring access to all those who need these solutions in a way which is viable for patients, society, and UCB.

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

• Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting antibody also in phase 3